Hematopoiesis News Volume 3.41 | Oct 18 2011

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis
Here, scientists show that an intramolecular interaction between the SH2 and kinase domains in Bcr-Abl is both necessary and sufficient for high catalytic activity of the enzyme. [Cell] Abstract

Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing
Here, researchers show that the repressor BCL11A is required in vivo for silencing of γ-globin expression in adult animals, yet dispensable for red cell production. [Science] Abstract | Press Release

Somatic Mutations in the Transcriptional Corepressor Gene BCORL1 in Adult Acute Myelogenous Leukemia
Here scientists report the discovery of novel somatic mutations in the transcriptional corepressor gene BCORL1 that is located on the X-chromosome. [Blood] Abstract

Galectin-3 Induced by Leukemia Microenvironment Promotes Drug Resistance and Bone Marrow Lodgment in Chronic Myelogenous Leukemia
In this study, researchers investigated the molecular mechanisms for bone marrow (BM) microenvironment-mediated drug resistance and BM lodgment in chronic myelogenous leukemia. [Proc Natl Acad Sci USA] Abstract

Enrichment of Functionally Distinct Mouse Hematopoietic Progenitor Cell Populations Using CD62L
The details of the bifurcation of the lymphoid and myeloid lineages following commitment by multipotent progenitor cells remain a topic of controversy. Investigators report that the surface glycoprotein CD62L can be characterized as a novel marker of this and other stages of early hematopoietic differentiation. [J Immunol] Abstract

Combined Preconditioning and In Vivo Chemoselection with 6-Thioguanine Alone Achieves Highly Efficient Reconstitution of Normal Hematopoiesis with HPRT Deficient Bone Marrow
Here scientists have developed a novel and highly efficient strategy employing 6-thioguanine as a single agent for both conditioning and in vivo chemoselection of hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient HSC. [Exp Hematol] Abstract

CLINICAL RESEARCH

Fludarabine Plus Alemtuzumab Versus Fludarabine Alone in Patients with Previously Treated Chronic Lymphocytic Leukemia: A Randomized Phase III Trial
Researchers compared the efficacy and safety of the combination of fludarabine and alemtuzumab with fludarabine monotherapy in previously treated patients with relapsed or refractory chronic lymphocytic leukemia. [Lancet Oncol] Abstract | Press Release

Front-Line Therapy with Second-Generation Tyrosine Kinase Inhibitors in Patients with Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
One hundred sixty-seven patients with newly diagnosed chronic myelogenous leukemia in chronic phase were treated with second-generation tyrosine kinase inhibitors in phase II trials (nilotinib, 81; dasatinib, 86). [J Clin Oncol] Abstract

Multi-Institutional Phase II Clinical and Pharmacogenomic Trial of Tipifarnib Plus Etoposide for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia
Investigators selected 2 comparable dose levels of tipifarnib plus etoposide for a randomized Phase II trial in 84 adults (age 70-90, median 76) who were not candidates for conventional chemotherapy. [Blood] Abstract

Athersys Confirms Completion of Patient Enrollment for Its Phase I Study of MultiStem^® for Hematopoietic Stem Cell Transplant Support
Athersys, Inc. announced that it has completed patient enrollment of the repeat dose arm of its clinical study involving administration of MultiStem^® to patients being treated for leukemia or other blood born cancers. [Athersys, Inc.] Press Release

Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase III Trial of Sapacitabine
Cyclacel Pharmaceuticals, Inc. announced that the independent Data Safety Monitoring Board of SEAMLESS, the Phase III, randomized, registration-directed study of sapacitabine in elderly patients with acute myeloid leukemia, recommended that the study should enter the randomized stage as planned. [Cyclacel Pharmaceuticals, Inc.] Press Release

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoietic community

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Contract Assay Service Technologist (STEMCELL Technologies)

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Quality Control Technologist – Cell Separation (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Postdoctoral Position – Regulation of Hematopoiesis by Extrinsic Regulators (Stem Cell Center Lund University)

Postdoctoral Fellow – Hematopoietic Stem Cells (City of Hope)

Postdoctoral Fellows – Blood Systems Research Institute (University of California, San Francisco)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.